Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase – Time to Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw strong trading volume on Monday . 8,380 shares changed hands during mid-day trading, an increase of 14% from the previous session’s volume of 7,321 shares.The stock last traded at $14.10 and had previously closed at $13.79.

Pharming Group Stock Performance

The company’s 50-day moving average price is $12.94 and its 200 day moving average price is $10.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The stock has a market capitalization of $980.38 million, a PE ratio of -110.08 and a beta of 0.05.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The firm had revenue of $93.20 million during the quarter, compared to analysts’ expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,979 shares of the company’s stock, valued at approximately $32,000. 0.03% of the stock is owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.